Ardelyx, Inc. (ARDX): Price and Financial Metrics
GET POWR RATINGS... FREE!
ARDX POWR Grades
- Growth is the dimension where ARDX ranks best; there it ranks ahead of 96.63% of US stocks.
- The strongest trend for ARDX is in Growth, which has been heading up over the past 179 days.
- ARDX's current lowest rank is in the Stability metric (where it is better than 3.44% of US stocks).
ARDX Stock Summary
- With a price/sales ratio of 25.39, ARDELYX INC has a higher such ratio than 94.76% of stocks in our set.
- With a year-over-year growth in debt of -43.22%, ARDELYX INC's debt growth rate surpasses merely 6.63% of about US stocks.
- Revenue growth over the past 12 months for ARDELYX INC comes in at -17.17%, a number that bests merely 9.45% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to ARDELYX INC, a group of peers worth examining would be MRIN, TTNP, WISA, EMKR, and AAOI.
- Visit ARDX's SEC page to see the company's official filings. To visit the company's web site, go to www.ardelyx.com.
ARDX Valuation Summary
- In comparison to the median Healthcare stock, ARDX's price/sales ratio is 862.89% higher, now standing at 46.7.
- ARDX's EV/EBIT ratio has moved up 30.7 over the prior 102 months.
Below are key valuation metrics over time for ARDX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ARDX | 2022-11-01 | 46.7 | 4.6 | -1.8 | -1.7 |
| ARDX | 2022-10-31 | 44.6 | 4.4 | -1.7 | -1.7 |
| ARDX | 2022-10-28 | 43.1 | 4.2 | -1.7 | -1.6 |
| ARDX | 2022-10-27 | 41.1 | 4.0 | -1.6 | -1.5 |
| ARDX | 2022-10-26 | 41.7 | 4.1 | -1.6 | -1.5 |
| ARDX | 2022-10-25 | 40.5 | 4.0 | -1.6 | -1.5 |
ARDX Growth Metrics
- Its 2 year net income to common stockholders growth rate is now at -67.91%.
- Its 3 year net income to common stockholders growth rate is now at -52.44%.
- Its 2 year cash and equivalents growth rate is now at -55.54%.
The table below shows ARDX's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 9.009 | -123.797 | -114.136 |
| 2022-06-30 | 5.196 | -132.959 | -134.83 |
| 2022-03-31 | 3.983 | -135.954 | -153.081 |
| 2021-12-31 | 10.097 | -152.551 | -158.165 |
| 2021-09-30 | 10.877 | -130.672 | -150.807 |
| 2021-06-30 | 12.417 | -115.96 | -125.328 |
ARDX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ARDX has a Quality Grade of C, ranking ahead of 26.73% of graded US stocks.
- ARDX's asset turnover comes in at 0.061 -- ranking 306th of 682 Pharmaceutical Products stocks.
- XBIO, CBAY, and BPTH are the stocks whose asset turnover ratios are most correlated with ARDX.
The table below shows ARDX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.061 | 0.919 | -0.887 |
| 2021-03-31 | 0.063 | 0.912 | -0.724 |
| 2020-12-31 | 0.036 | 0.981 | -0.618 |
| 2020-09-30 | 0.035 | 0.982 | -0.579 |
| 2020-06-30 | 0.040 | 0.911 | -0.719 |
| 2020-03-31 | 0.035 | 0.908 | -0.806 |
ARDX Price Target
For more insight on analysts targets of ARDX, see our ARDX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $6.21 | Average Broker Recommendation | 1.62 (Moderate Buy) |
ARDX Stock Price Chart Interactive Chart >
ARDX Price/Volume Stats
| Current price | $1.84 | 52-week high | $2.19 |
| Prev. close | $1.77 | 52-week low | $0.49 |
| Day low | $1.73 | Volume | 6,831,900 |
| Day high | $1.94 | Avg. volume | 4,497,110 |
| 50-day MA | $1.42 | Dividend yield | N/A |
| 200-day MA | $0.98 | Market Cap | 344.93M |
Ardelyx, Inc. (ARDX) Company Bio
Ardelyx is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative, minimally-systemic, small molecule therapeutics that work exclusively in the gastrointestinal tract to treat cardio-renal, gastrointestinal and metabolic diseases. The company was founded in 2007 and is based in Fremont, California.
Latest ARDX News From Around the Web
Below are the latest news stories about ARDELYX INC that investors may wish to consider to help them evaluate ARDX as an investment opportunity.
Ardelyx to Present at the 34th Annual Piper Sandler Healthcare ConferenceArdelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that management will participate in a fireside discussion at the 34th Annual Piper Sandler Healthcare Conference on Thursday, December 1, 2022, at 10:00 a.m. ET in New York City. |
2 Biotech Stocks That Can Rocket Higher in 2023, According to Wall StreetIf your answer's yes, the biotech industry has you covered. Last week, two biotech companies independently announced some surprisingly good news that got the attention of investment banks on Wall Street. Ardelyx (NASDAQ: ARDX) is a commercial-stage biotech that markets a drug called Ibsrela for irritable bowel syndrome. |
Ardelyx (ARDX) Up 41% After FDA Committee Endorses CKD DrugThe FDA's CRDAC recommends granting marketing approval to Ardelyx's (ARDX) oral pill to control serum phosphorus in adult patients with chronic kidney disease on dialysis. |
Analyst Sees This Kidney Disease Company's Stock Could Rise Sixfold, But Lists Two IssuesPiper Sandler raised its price target on Ardelyx Inc (NASDAQ: ARDX) to $8 from $3 and upgraded to Overweight from a Neutral rating. The upgrade follows a surprisingly positive advisory committee vote of 9-4 in favor of tenapanor as monotherapy and 10-2 (1 abstention) as combo therapy for controlling serum phosphorus in dialysis-dependent chronic kidney disease (CKD). While we found the vote itself remarkable, it was more meaningful that the vote was not split along “party lines,” the analyst wro |
Fed Comments Continue To Weigh On Stocks MiddayStocks are firmly lower midday, as bond yields rise following hawkish comments from St. Louis Federal Reserve President James Bullard. |
ARDX Price Returns
| 1-mo | 33.33% |
| 3-mo | 82.18% |
| 6-mo | N/A |
| 1-year | 106.16% |
| 3-year | 4.10% |
| 5-year | 23.70% |
| YTD | 67.27% |
| 2021 | -31.99% |
| 2020 | -13.79% |
| 2019 | 319.28% |
| 2018 | -72.88% |
| 2017 | -53.52% |
Continue Researching ARDX
Here are a few links from around the web to help you further your research on Ardelyx Inc's stock as an investment opportunity:Ardelyx Inc (ARDX) Stock Price | Nasdaq
Ardelyx Inc (ARDX) Stock Quote, History and News - Yahoo Finance
Ardelyx Inc (ARDX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...